Avalo Therapeutics (AVTX)
Develops an anti-IL-1β antibody for immune-mediated inflammatory diseases.
$19.35
Pre-market−0.01 (−0.05%)
At close$19.36(+2.16%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions109 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 58.00% | 31.10M shares | |
| Insiders11 holders · as of Sep 1, 2026 | 0.71% | 381.1K shares | |
| Strategic holders1 holder · as of May 29, 2026 | 5.70% | 3.06M shares | |
| Otherremainder | ≈ 35.59% | 19.09M shares |
53.63M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Mar 31, 2026
109 holders · 31.10M shares · 34 new positions · 65 increased · 22 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 2.88M | 5.37% | +2.66M | May 15, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.16M | 4.03% | +2.16Mnew | May 15, 2026 |
| Caligan Partners LP | 1.64M | 3.05% | +753.5K | May 15, 2026 |
| BVF Inc/IL | 1.63M | 3.04% | +277.6K | May 15, 2026 |
| Avoro Capital Advisors LLC | 1.41M | 2.63% | +1.41Mnew | May 15, 2026 |
| Affinity Asset Advisors, LLC | 1.34M | 2.50% | +289.8K | May 14, 2026 |
| Nantahala Capital Management, LLC | 1.24M | 2.30% | 0 | May 15, 2026 |
| UBS Group AG | 1.14M | 2.13% | +664.2K | May 5, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Ikarian Capital, LLCincl. Neil Shahrestani | 10.02% | 970.4K | 13G | Oct 7, 2024 ↗ |
| Commodore Capital LP | 9.90% | 5.72M | 13G | Jun 18, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 2.46M | 13G | May 15, 2026 ↗ |
| OrbiMed Advisors LLCincl. OrbiMed Capital GP IX LLC | 9.90% | 967.0K | 13G | Nov 14, 2024 ↗ |
| T. Rowe Price Investment Management, Inc. | 9.50% | 2.16M | 13G | May 15, 2026 ↗ |
| Nantahala Capital Management, LLC | 9.39% | 1.24M | 13G | Nov 14, 2025 ↗ |
| TCG Crossover GP II, LLC | 7.90% | 3.02M | 13G | May 12, 2026 ↗ |
| Affinity Healthcare Fund, LP | 7.65% | 1.01M | 13G | Nov 13, 2025 ↗ |
| Caligan Partners LP | 7.20% | 1.64M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 6.50% | 3.42M | 13G | Jul 27, 2026 ↗ |
| FMR LLC | 6.10% | 3.19M | 13G | Jun 5, 2026 ↗ |
| Deep Track Capital, LP | 5.81% | 3.06M | 13G | May 29, 2026 ↗ |
| Avoro Capital Advisors LLC | 5.75% | 1.41M | 13G | May 15, 2026 ↗ |
| Affinity Asset Advisors, LLC | 5.50% | 1.34M | 13G | May 14, 2026 ↗ |
| Biotechnology Value Fund L P | 5.40% | 1.26M | 13G | May 15, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 28, 2026 | Mittie Doyleofficer: Chief Medical Officer | Sale | 679 | $20.00 | 51,776 |
| Aug 17, 2026 | Mittie Doyleofficer: Chief Medical Officer | Sale | 1,000 | $20.00 | 51,776 |
| Aug 18, 2026 | Christopher Ryan Sullivanofficer: Chief Financial Officer | Sale | 31,031 | $20.05 | 39,900 |
| Aug 17, 2026 | Christopher Ryan Sullivanofficer: Chief Financial Officer | Sale · 2 lots | 41,694 | $19.86 | 39,900 |
| Aug 10, 2026 | Mittie Doyleofficer: Chief Medical Officer | Sale | 679 | $20.00 | 51,776 |
| Aug 11, 2026 | Jennifer Rileyofficer: Chief Strategy Officer | Sale | 2,655 | $19.59 | 37,041 |
| Jul 27, 2026 | Mittie Doyleofficer: Chief Medical Officer | Sale | 1,000 | $20.00 | 51,776 |
| Jun 30, 2026 | Mittie Doyleofficer: Chief Medical Officer | Sale | 4,654 | $20.00 | 51,776 |
| Jun 23, 2026 | Mittie Doyleofficer: Chief Medical Officer | Sale | 1,450 | $18.00 | 51,776 |
| May 28, 2026 | Mittie Doyleofficer: Chief Medical Officer | Sale | 679 | $16.00 | 47,122 |
CongressHouse and Senate disclosures
Not reported.